The acute toxicity and in vivo antitumour activity against L1210 leukemia of triphenyltin 3,5-diisopropylsalicylate, bis (di-n-butyl-(s)-2-pyrrolidone-5-carboxylato)tin oxide and di-n-butyltin bis(3-amino-4-methylbenzoate)

In Vivo. 1993 Mar-Apr;7(2):171-4.

Abstract

Triphenyltin 3,5-di-isopropylsalicylate, compound 1, is characterized by a maximum tolerated dose (MTD) of 20 mg/kg. Bis[di-n-butyl(2-pyrrolidone-5-carboxylato)tin] oxide, compound 2, and (di-n-butyltin bis(3-amino-4-methyl-benzoate), compound 3, exhibit similar acute toxicities (MTD = 8 mg/kg) despite their lower in vitro activity, as compared to compound 1, against the two human tumor cell lines MCF-7 and WiDr. All three are inactive in vivo against L1210 leukemia in mice.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminobenzoates / therapeutic use
  • Aminobenzoates / toxicity*
  • Animals
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Agents / toxicity*
  • Leukemia L1210 / drug therapy*
  • Male
  • Mice
  • Mice, Inbred DBA
  • Organotin Compounds / therapeutic use
  • Organotin Compounds / toxicity*
  • Pyrrolidinones / therapeutic use
  • Pyrrolidinones / toxicity*
  • Salicylates / therapeutic use
  • Salicylates / toxicity*
  • meta-Aminobenzoates

Substances

  • Aminobenzoates
  • Antineoplastic Agents
  • Organotin Compounds
  • Pyrrolidinones
  • Salicylates
  • meta-Aminobenzoates
  • di-n-butyltin bis(3-amino-4-methylbenzoate)
  • triphenyltin 3,5-diisopropylsalicylate
  • bis(di-n-butyl-2-pyrrolidone-5-carboxylato)tin oxide